Prisma Health Outsourcing Facility, Simpsonville, SC
Is Prisma Health Outsourcing Facility registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does Prisma Health Outsourcing Facility hold a South Carolina pharmacy license?
State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
Has Prisma Health Outsourcing Facility had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Aug 21, 2023) for Prisma Health Outsourcing Facility. State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Prisma Health Outsourcing Facility
- Location
- Simpsonville, SC
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Aug 21, 2023
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 4 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Prisma Health Outsourcing Facility, a 503B facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Aug 21, 2023 | FMD-145 letter | FMD-145 Letter Issued 08/21/2023 | Not linked by FDA |
| Mar 3, 2023 | Form 483 | 483 Issued 03/03/2023 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Prisma Health Outsourcing Facility, Simpsonville, SC (FEI number 3015162096), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 3, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015162096 | 1198795 |
Form 483s FDA has published for this site
- Mar 3, 2023: Form 483 to Prisma Health Outsourcing Facility, published Jun 28, 2023. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 4 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 23, 2023 to Mar 3, 2023: 4 observations
- Firm on the cover
- Prisma Health Outsourcing Facility, 1071 Holland Rd Ste 2, Simpsonville, SC 29681-5709 ·~
- FEI number
- 3015162096
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Specifically,
A. Your firm was found d to have a plastic sleeve used to hold a laminated form affixed the side of your ISO 5 LAFUs within your firm's ISO 7 Filling Suite to show the operational status and manufacturing activities occurring within the unit. Neither the plastic sleeve nor the laminated sheet was part of your firm's cleaning and disinfectant schedule. It has not been deemed cleaned/disinfected the pharmacist/interim quality personnel.
B. Your firm's compounding technicians were observed writing on paper batch records within your firm's ISO 7 Filling Suite during aseptic processing of the sterile drug, Ketamine 30mg/6mL, Lot <Redacted B4> processed on 2/24/2023. Paper within the cleanroom has the potential of shedding and increasing the particulate count in addition to being a source of cross contamination within the ISO 7 Filling suite. The paper batch records were observed being placed atop the nonprotected laptop keyboard sitting on the stainless steel table.
C. ...
Observation 2
Aseptic processing areas are deficient in that floors and walls are not smooth and/or hard surfaces that are easily cleanable.
Specifically,
A. Your firm use <Redacted B4> trash cans, which has a hard to clean and disinfect surface within your ISO 7 Gowning and ISO 7 Filling suite containing your firm's <Redacted B4> ISO 5 LAFU. The surface has the potential of retaining foreign particulates and microbiological organisms that may pose a risk to aseptically processed drug products.
B. Your firm uses a laptop computer on a stainless steel table within your firm's ISO 7 Filling Suite used for data entry during aseptic processing. The none protected laptop keyboard has hard to clean areas that prevent adequate cleaning and disinfecting resulting in potential sites for microbiological growth and possible site for cross contamination. Your firm's technician was observed during the production of the sterile drug, Ketamine HCL Injection Solution 30 mg/6 mL (5mg/mL) Syringe, Qty. <Redacted B4> syringes, Lot <Redacted B4>, fail to disinfect <Redacted B4> sterile gloves prior to returning to the ISO 5 LAFU following data entry. ...
Observation 3
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, Your firm's documented procedure for responding to your firm's <Redacted B4> monitoring System is inadequate. For example, your firm's procedure, Addressing Alarms [ssued by <Redacted B4> Monitoring System, SOP.QC.006 fail to include a list of possible responses when an Alert/ Action Limit has been reached and a criteria/specification for the selection of each firm created responses. On 6/1/2022 at 10:30 pm, during a review of your firm's differential pressure alerts, one of the responses found was "Self-Correction". Your firm's procedure failed to establish a definition to the meaning/ specification for the selection of this response.
specification for the selection of this response.
Observation 4
Reporting Issue
1. Your facility failed to submit a complete report to FDA for the June 2021, December 2021, June 2022, and December 2022 product reporting periods, identifying all the drug products that you compounded during the previous 6-month period, such as Ketamine HCI injection solution 10mg/2mL, Ketamine injection solution 100mg/20mL, Ketamine injection solution 30mg/6mL, and Phenylephrine HCI in NS 50mg/250mL. [Section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]].
State board of pharmacy records
State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.